Meshima & Cancer
Explore mushroom research and guides on meshima & cancer.
Meshima and Breast Cancer: Research on Hormone-Sensitive Tumors
Meshima inhibits invasive breast cancer cells via AKT inhibition, and its hispolon compound reduces ER-α expression. What the preclinical research shows.
Meshima and Cancer Cell Apoptosis: How It Triggers Death
Meshima triggers cancer cell apoptosis through two pathways. Hispolon activates caspase-3, -8, and -9, and sensitizes cells to TRAIL. All data is preclinical.
Meshima and Cancer: The Complete Research Review
Meshima (Phellinus linteus) has the strongest antitumor activity among mushrooms tested in 40+ years of Japanese research. Here's the complete evidence, including what the 2024 data complicates.
Meshima and Prostate Cancer: Preclinical Evidence
Phellinus linteus has two prostate cancer studies in high-impact journals. Response varies by androgen receptor status; tumor regression confirmed in vivo.
Phellinus linteus: How It Inhibits Tumor Growth
Phellinus linteus tumor growth inhibition mapped across four molecular pathways: cell cycle arrest, Wnt disruption, AKT inhibition, and MDM2 targeting.